ArticleComplementary medicine research2026
Case Series: Real-Life Experience with Vitex Agnus-Castus Extract Ze 440 Medication in Adolescents.
Article in Complementary medicine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMenstrual disorders are common in adolescents and can significantly impact quality of life. Nonhormonal treatment options are of particular interest in this population, especially for those not requiring contraception. Vitex agnus-castus (VAC) extract Ze 440 is a well-established phytotherapeutic agent shown to be effective in adult women, though clinical data in adolescents remain limited.
methodsThis case series presents real-life clinical experience with Ze 440 in 6 adolescent patients aged 12-17 years with various menstrual disorders. Patients were followed in routine clinical practice for up to 6 months.
resultsTreatment with Ze 440 demonstrated good efficacy in relieving dysmenorrhea and stabilizing the menstrual cycle. In several cases, the use of non-steroidal anti-inflammatory drugs (NSAIDs) could be reduced or discontinued. Two patients with pronounced hypermenorrhea required additional therapy with tranexamic acid; one of them was switched to norethisterone after 6 months due to poor tolerance of tranexamic acid. Ze 440 was well tolerated, and no adverse events were reported.
conclusionZe 440 appears to be a practical, well tolerated, nonhormonal option for managing menstrual disorders in adolescents. It supports the natural menstrual cycle without hormonal suppression. Regular clinical follow-up is recommended to optimize treatment outcomes and adjust therapy as needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.